Scientist, Inflammation at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

PhD or equivalent degree
At least 3 years of relevant post-graduate independent research or drug development experience in immunology, fibrotic and autoimmune diseases
Experience and knowledge in human fibrotic and inflammatory diseases, immunology research (preferred)
Top expertise in previous research areas
Critical analytical skills

Responsibilities

Design and execute human-relevant experiments in primary blood/tissue (gut, liver, skin, lung, synovium); perform responder vs non-responder comparisons, perturbation studies, and pathway/target validation
High-dimensional profiling: plan/execute high-parameter flow or mass cytometry (≥18-color), receptor occupancy and phospho-flow; single-cell (scRNA-seq/ATAC) and spatial transcriptomics/proteomics; multiplex IF/IHC and quantitative pathology
Endotype & biomarker strategy: define disease-agnostic PD/RO and endotype markers; qualify/validate fit-for-purpose assays (ELISA/MSD, qPCR/ddPCR, ligand-binding, RO/TE) and transfer to internal labs/CROs under GCLP
Sample strategy & operations: contribute to protocol/IB biomarker sections; specify pre-analytical handling, chain-of-custody and kitting; support CRO selection/oversight; ensure data integrity and timely delivery
Data integration & interpretation: partner with Biostats and Bioinformatics teams on analysis plans; integrate multi-omic/imaging and clinical data; craft succinct go/no-go narratives for governance
Influence without authority: coordinate across functions; document SOPs; contribute to safety/quality culture; mentor peers and have a growth mindset
Lead reverse translation workstreams: interrogate clinical/real-world datasets with Clinical, Biostats, and Bioinformatics; generate mechanistic hypotheses for response/non-response

Skills

biomarker discovery

translational research

primary human cells

tissue assays

ex vivo experiments

responder analysis

inflammation biology

fibrotic diseases

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free